Virax Biolabs’ CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

LONDON, July 16, 2026 /PRNewswire/ – Virax Biolabs Group Limited (Nasdaq: VRAX) has published a shareholder update providing context on several recent developments, including the filing of its fiscal 2026 Annual Report, the multi-country commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets, the completion of a preferred investment option exercise generating approximately $3.3 million in gross proceeds, and the restoration of Nasdaq minimum bid price compliance. The update also outlines the Company’s priorities for ViraxImmune™, ImmuneSelect and continued commercial execution. Read the full Press Release here

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

LONDON, July 09, 2026 /PRNewswire/ – Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”) today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company’s ImmuneSelect research-use immune profiling product line. The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue opportunities and regional commercial expansion. Key highlights: Commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets, with exclusivity subject to agreed minimum purchase and performance requirements. Supports near-term potential revenue opportunities through purchase-order-driven supply of Virax’s commercially available ImmuneSelect product line Provides access to Fosun Diagnostics’ established regional commercial infrastructure and customer network. Framework supports expansion into additional products, higher-volume supply arrangements and potential OEM/private-label opportunities. Near-term commercial opportunity separate from ViraxImmune™, the Company’s in-development diagnostic platform. Read the full Press Release here